[
    [
        {
            "time": "2018-01-17",
            "original_text": "复星医药：两子公司获批准白血病治疗药物临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "白血病",
                    "治疗药物",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：两子公司获批准白血病治疗药物临床试验",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-17",
            "original_text": "复星医药：创新药全面布局 买入评级",
            "features": {
                "keywords": [
                    "复星医药",
                    "创新药",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：创新药全面布局 买入评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-17",
            "original_text": "【重磅！】上海钢联深度：利润拐点在即，进入长期成长轨道（Fintech系列深度之七）",
            "features": {
                "keywords": [
                    "上海钢联",
                    "利润拐点",
                    "长期成长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "钢铁",
                    "金融科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【重磅！】上海钢联深度：利润拐点在即，进入长期成长轨道（Fintech系列深度之七）",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-17",
            "original_text": "【医药-复星医药(600196)】江琦、张天翼：从单抗到小分子，创新药全面布局 - 20180117",
            "features": {
                "keywords": [
                    "复星医药",
                    "单抗",
                    "小分子",
                    "创新药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药-复星医药(600196)】江琦、张天翼：从单抗到小分子，创新药全面布局 - 20180117",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-14",
            "original_text": "【山证医药】医药生物行业周报（20180108-20180114）：2017年度业绩预告陆续发布",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业周报",
                    "业绩预告"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【山证医药】医药生物行业周报（20180108-20180114）：2017年度业绩预告陆续发布",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-01-17",
            "original_text": "银河生物控股公司马力喏首席科学顾问陈思毅：两三年后CAR-T疗法赛道将现“裸泳者”",
            "features": {
                "keywords": [
                    "银河生物",
                    "CAR-T疗法",
                    "裸泳者"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "银河生物控股公司马力喏首席科学顾问陈思毅：两三年后CAR-T疗法赛道将现“裸泳者”",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]